Loading clinical trials...

Avapritinib Rollover Study | Clinical Trials | Clareo Health

RECRUITINGPHASE4

Avapritinib Rollover Study

An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study

NCT06748001•Blueprint Medicines Corporation

Summary

The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participated in a Blueprint Medicines sponsored avapritinib clinical study. The Sponsor reserves the right to not roll over patients who have been on drug hold for an extended time period.
•Completed End of Trial / End of Study (EOT/EOS) visit in the parent study and demonstrated compliance with the parent study requirements.
•Continue to clinically benefit from treatment with avapritinib.
•Able to give written informed consent.
•Agree to continue to use highly effective contraception as defined in this protocol.
•Female patients of childbearing potential must have negative highly sensitive serum pregnancy test within 20 days before the first dose of avapritinib. Women of nonchildbearing potential do not require this test.

Exclusion Criteria

•Participant is participating in another interventional study.
•Participant is unwilling or unable to comply with study procedures and study restrictions.
•Participant is breastfeeding.
•Other protocol-defined criteria apply.

Locations (7)

Universitair Ziekenhuis Antwerpen (UZA)

Edegem, Belgium

The Hospital for Sick Children

Toronto, Ontario, Canada

A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno

Salerno, Italy

Universitair Medisch Centrum Groningen

Groningen, Netherlands

Erasmus Medisch Centrum

Rotterdam, Netherlands

Oslo University Hospital

Oslo, Norway

Guys and St Thomas NHS Foundation Trust - St Thomas Hospital

London, United Kingdom

Key Dates

Start Date

November 28, 2024

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2027

Last Updated

February 9, 2026

Enrollment

ESTIMATED participants

Conditions

Mastocytosis, Systemic

Interventions

Avapritinib

DRUG

Contacts

Blueprint Medicines

CONTACT

617-714-6707 MedInfo@blueprintmedicines.com

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

NCT05186753

SSMMastocytosis, Indolent+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions